GlassScriptPhysician profile
Kevin L Schroeder
NPI 1982662078
$1,501.08
in general payments reported to CMS, 2019-2025
33 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $127 · 2021: $111 · 2022: $136 · 2023: $103 · 2024: $444 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464 · Travel and Lodging: $185 · Education: $37.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.72 |
| Travel and Lodging | $185.41 |
| Education | $37.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $295.00 | 2024 | |
| Jazz Pharmaceuticals INC. | $206.91 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $87.12 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $86.40 | 2019 | |
| Akebia Therapeutics INC | $77.86 | 2019-2024 | Vafseo |
| Novartis Pharmaceuticals Corporation | $62.19 | 2019-2025 | |
| Novo Nordisk INC | $56.81 | 2023-2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $54.31 | 2022-2023 | |
| Daiichi Sankyo INC. | $53.14 | 2019-2020 | |
| Baxter Healthcare | $38.39 | 2019 | |
| Ardelyx, INC. | $37.91 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $37.88 | 2024-2025 | Filspari |
| Mallinckrodt Enterprises LLC | $36.60 | 2019 | |
| Mallinckrodt Hospital Products INC. | $36.09 | 2020-2023 | Terlivaz |
| Horizon Therapeutics Plc | $30.23 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $23.69 | 2025 | Tarpeyo |
| Shire North American Group INC | $21.34 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.75 | 2020 | |
| Amgen INC. | $20.56 | 2024 | Tavneos |
| Mannkind Corporation | $20.08 | 2025 | |
| Apellis Pharmaceuticals, INC. | $19.98 | 2025 | |
| Vifor Pharma, INC. | $19.63 | 2019 | |
| Lundbeck LLC | $18.91 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.42 | 2024 | Jardiance |
| Nxstage Medical, INC. | $18.07 | 2023 | Nxstage System One, Pureflow Sl |
| Opko Pharmaceuticals, LLC | $17.69 | 2019 | |
| Genzyme Corporation | $16.43 | 2019 | |
| Genentech USA, INC. | $15.97 | 2019 | |
| Aurinia Pharma U.S., INC. | $14.91 | 2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $14.80 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.01 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.